Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07190261 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

StatusNot Yet Recruiting
PhasePhase 2
SponsorBing Han
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Bing Han
3 trials monitored
See all monitored trials
Glucocorticoids are the first-line treatment for wAIHA, but patients are prone to recurrence after dose reduction or discontinuation of glucocorticoids. Birgens et al. 's study found that approximately 55% of patients treated with prednisolone monotherapy experienced recurrence at 36 months. The overall response rate of second-line treatment with rituximab is 70-80%, but the recurrence rate reaches 50%. The response rates of other immunosuppressants, such as cyclosporine, cyclophosphamide, and azathioprine, are relatively low, approximately 30-50%. Patients with chronic hemolysis have recurrent episodes, which affect their survival and quality of life. New treatment methods need to be explored.
Trial Details
NCT Number NCT07190261
Lead Sponsor Bing Han
Conditions
(from sponsor)		 Autoimmune Hemolytic Anemia
Related terms Anemia, Hemolytic, Autoimmune
Enrollment 3 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov